Vicky L Funanage
Overview
Explore the profile of Vicky L Funanage including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
207
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Funanage V
Dela J Public Health
. 2022 May;
7(5):10-11.
PMID: 35619978
Advances in the field of human genetics over the past three decades have led to improvements in human health through development and availability of novel genetic testing approaches for diagnosis,...
2.
Kirwin S, Robbins K, Vinette K, Hirata L, Gripp K, Funanage V
Dela J Public Health
. 2022 May;
7(5):24-27.
PMID: 35619972
Chronic kidney disease (CKD) has major morbidity and mortality for children and adults. While in adults CKD often is associated with diabetic complications, genetic variants can be the underlying cause...
3.
Funanage V
Dela J Public Health
. 2021 Sep;
6(2):18-19.
PMID: 34467102
The Coronavirus disease 2019 (COVID-19) pandemic caused by SARS-CoV-2 has resulted in a global health emergency with major social and economic disruption. With no effective treatment or vaccine available, and...
4.
Cook K, Duong B, Seligson N, Arn P, Funanage V, Gripp K, et al.
Clin Pharmacol Ther
. 2021 Jul;
110(3):555-558.
PMID: 34254671
No abstract available.
5.
Rahawi S, Naik H, Blake K, Obeng A, Wasserman R, Seki Y, et al.
J Hum Genet
. 2020 Jan;
65(5):437-444.
PMID: 31983733
Increasing enthusiasm for clinical pharmacogenetic testing and the availability of pharmacogenetic-based guidelines indicate that pediatricians will increasingly be expected to interpret and apply pharmacogenetic test results into medical care. Previous...
6.
Hurd L, Kirwin S, Boggs M, Mackenzie W, Bober M, Funanage V, et al.
Am J Med Genet A
. 2015 Aug;
167A(10):2286-93.
PMID: 26249260
Transient receptor potential cation channel, subfamily V, member 4 (TRPV4) is a polymodal modulated non-selective cation channel required for normal development and maintenance of bone and cartilage. Heterozygous mutations of...
7.
Stabley D, Harris A, Holbrook J, Chubbs N, Lozo K, Crawford T, et al.
Mol Genet Genomic Med
. 2015 Aug;
3(4):248-57.
PMID: 26247043
Proximal spinal muscular atrophy (SMA) is an early-onset motor neuron disease characterized by loss of α-motor neurons and associated muscle atrophy. SMA is caused by deletion or other disabling mutation...
8.
Kirwin S, Vinette K, Gonzalez I, Abdulwahed H, Al-Sannaa N, Funanage V
Mol Genet Genomic Med
. 2014 Feb;
1(2):113-7.
PMID: 24498607
Spinal muscular atrophy (SMA), the most common autosomal recessive cause of infant death, is typically diagnosed by determination of SMN1 copy number. Approximately 3-5% of patients with SMA retain at...
9.
Balagopal P, Gidding S, Buckloh L, Yarandi H, Sylvester J, George D, et al.
Obesity (Silver Spring)
. 2010 Jan;
18(9):1747-53.
PMID: 20094040
The aims of this study are to examine in children: (i) obesity-related alterations in satiety factors such as leptin, ghrelin, and obestatin; (ii) the link between satiety factors and cardiometabolic...
10.
Wu C, Gomez-Curet I, Funanage V, Scavina M, Wang W
BMC Cell Biol
. 2009 May;
10:40.
PMID: 19445707
Background: Deletion or mutation(s) of the survival motor neuron 1 (SMN1) gene causes spinal muscular atrophy (SMA). The SMN protein is known to play a role in RNA metabolism, neurite...